The FDA has approved Rezdiffra, the first medication for severe non-alcoholic fatty liver disease, showing improvement in liver scarring in NASH patients. NASH affects millions, linked to health issues like high blood pressure and diabetes. Rezdiffra targets root causes of NASH, with common side effects of diarrhoea and nausea.
from Science News - Times of India https://ift.tt/tehlPT2
via
from Science News - Times of India https://ift.tt/tehlPT2
via
Comments
Post a Comment